Adam S. Grossman, a director and officer at ADMA Biologics, Inc., has filed a notice to sell 189,000 shares of the company’s common stock. This filing is significant as it highlights the ongoing activity and trends within the biological products sector. The shares are being sold as part of a structured plan related to stock options and restricted stock units.

Background

ADMA Biologics, Inc. is a company incorporated in Delaware, primarily engaged in the biological products industry. The company is listed on NASDAQ under the SEC file number 001-36728. Its business is centered around developing and commercializing specialty biopharmaceutical products for the treatment of immune deficiencies.

What the Filing Says

The SEC filing, dated November 5, 2026, indicates that Grossman plans to sell 189,000 shares, which have an aggregate market value of approximately $1,980,720. The shares were acquired through the exercise of stock options and the vesting of restricted stock units, with the most recent acquisition occurring on the same day as the filing.

Impact

This sale may affect investors and market participants as it reflects the liquidity and trading strategies of insiders at ADMA Biologics. The sale of shares by a director might influence investor perceptions of the company’s future prospects.

What's Next

The filing does not say what happens next.